Italy's Newron Pharmaceuticals SpA has gained FDA approval to market its Parkinson's disease (PD) drug, Xadago (safinamide), for patients who are currently taking levodopa/carbidopa and experiencing "off" episodes, or periods in which their medications are not working well, causing an increase in PD symptoms.